Search Result

Results for "

PDK1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PDK-1 (31) Akt (11) Androgen Receptor (1) Antibiotic (1) Apoptosis (11) Autophagy (6) Bacterial (1) c-Myc (1) CDK (1) EGFR (1) ERK (2) FGFR (1) FOXO (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (3) HPV (1) HSP (2) IKK (3) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (1) JNK (2) MARK (1) MDM-2/p53 (1) MEK (1) Mitochondrial Metabolism (2) Mitophagy (1) Monoamine Oxidase (1) mTOR (3) Oxidative Phosphorylation (1) Parasite (1) PDHK (8) PI3K (3) PROTACs (1) PTEN (1) Pyruvate Kinase (2) Quinone Reductase (1) Reactive Oxygen Species (ROS) (3) Reference Standards (3) Ribosomal S6 Kinase (RSK) (1) Ser/Thr Protease (1) Wee1 (1)
By Research Areas:	Cancer (43) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (3)

By Targets:

PDK-1 (31)

Akt (11)

Androgen Receptor (1)

Antibiotic (1)

Apoptosis (11)

Autophagy (6)

Bacterial (1)

c-Myc (1)

CDK (1)

EGFR (1)

ERK (2)

FGFR (1)

FOXO (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (3)

HPV (1)

HSP (2)

IKK (3)

Isocitrate Dehydrogenase (IDH) (1)

Isotope-Labeled Compounds (1)

JNK (2)

MARK (1)

MDM-2/p53 (1)

MEK (1)

Mitochondrial Metabolism (2)

Mitophagy (1)

Monoamine Oxidase (1)

mTOR (3)

Oxidative Phosphorylation (1)

Parasite (1)

PDHK (8)

PI3K (3)

PROTACs (1)

PTEN (1)

Pyruvate Kinase (2)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (3)

Ribosomal S6 Kinase (RSK) (1)

Ser/Thr Protease (1)

Wee1 (1)

By Research Areas:

Cancer (43)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PDK-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0645

Dicoumarol Maximum Cited Publications 11 Publications Verification Dicumarol	Quinone Reductase PDHK	Cancer
Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and *PDK1* with IC₅₀s of 0.37 and 19.42 μM, respectively.

HY-10514

BX795 Maximum Cited Publications 38 Publications Verification	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of *PDK1, with an IC₅₀* of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-N0047

Polyphyllin I 5 Publications Verification	JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of *PDK1/Akt/mTOR* signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-11005

BX-912 5+ Cited Publications	PDK-1 Apoptosis	Cancer
BX-912 is a direct, selective, and ATP-competitive *PDK1* inhibitor (IC₅₀=26 nM). BX-912 blocks PDK1/Akt signaling in tumor cells and inhibits the anchorage-dependent growth of a variety of tumor cell lines in culture or induces apoptosis .

HY-14981

GSK2334470 10+ Cited Publications	PDK-1	Cancer
GSK2334470 is a highly specific and potent inhibitor of *PDK1* with an IC₅₀ of 10 nM.

HY-10547

OSU-03012 5+ Cited Publications AR-12; PDK1 inhibitor AR-12	PDK-1 Autophagy	Cancer
OSU-03012 (AR-12; PDK1 inhibitor AR-12) is a blood-brain permeable *PDK-1* inhibitor with an IC₅₀ of 5 μM .

HY-12492

VER-246608 4 Publications Verification	PDHK	Cancer
VER-246608 is a potent and ATP-competitive inhibitor of pyruvate dehydrogenase kinase (PDK) with IC₅₀s of 35 nM, 40 nM, 84 nM, and 91 nM for *PDK-1, PDK-3, PDK-2, and PDK-4*, respectively.

HY-N6769

Radicicol 4 Publications Verification Monorden	HSP Bacterial Antibiotic Parasite	Infection
Radicicol is an inhibitor of Hsp90 with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-124379

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV Apoptosis PDK-1	Infection Neurological Disease Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the *PDK1/Akt* pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats .

HY-14440

MP7 2 Publications Verification PDK1 inhibitor	PDK-1	Cancer
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent CDK1 and CDK2 inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) .

HY-19564

JX06 5+ Cited Publications	PDHK Apoptosis	Cancer
JX06 is a potent, selective and covalent inhibitor of PDK. JX06 inhibits *PDK1, PDK2* and PDK3 with IC₅₀s of 49 nM, 101 nM, and 313 nM, respectively. JX06 inhibits PDK1 activity via covalently binding to a cysteine residue in an irreversible manner. JX06 shows significant antitumor activity .

HY-121744

PS10 5+ Cited Publications	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase

HY-121629

PS210	PDK-1	Cancer
PS210 is a potent and selective *PDK1* activator with a K_d of 3 μM and targets the PIF-binding pocket of *PDK1. PS210 is inactive against other protein kinases, including PDK1* downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of *PDK1, inhibiting* the phosphorylation and activation of S6K .

HY-13842

BX517 2 Publications Verification	PDK-1	Cancer
BX517 is a potent and selective inhibitor of *PDK1* with IC₅₀ of 6 nM.

HY-114645

PDK1-IN-RS2	PDK-1	Cancer
PDK1-IN-RS2 is a mimic of peptide docking motif (PIFtide) and is a substrate-selective *PDK1* inhibitor with a K_d of 9 μM. PDK1-IN-RS2 suppresses the activation of the downstream kinases S6K1 by *PDK1* .

HY-149814

PDK-IN-1	PDHK HSP	Cancer
PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC₅₀ values of 0.03 and 0.1 μM for *PDK1* and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass .

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR .

HY-W070306

PDK1-IN-1	PDK-1 FGFR Wee1 MARK	Neurological Disease Cancer
PDK1-IN-1 (Compound 2-11) is a *PDK1* inhibitor. PDK1-IN-1 is also useful as inhibitor of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. PDK1-IN-1 selectively inhibits microtubule affinity regulating kinase (MARK). PDK1-IN-1 can be used for researches of myeloproliferative disorders, cancer and Alzheimer's disease .

HY-10515

BX-320	PDK-1	Cancer
BX-320 is a selective, ATP-competitive, orally acitive, and direct *PDK1* inhibitor with an IC₅₀ of 30 nM in a direct kinase assay format. BX-320 also induces apoptosis. Anticancer effect .

HY-W998345

SMART1	PROTACs PDK-1 Akt	Cancer
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the *PDK1-Akt* signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models.(Blue: CRBN ligand; Black: linker; Pink: Smurf1 ligand (Smurf1-L)) .

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer .

HY-106263B

Tyroserleutide hydrochloride	PTEN PDK-1 MDM-2/p53 Apoptosis Akt	Cancer
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and *PDK1. Tyroserleutide hydrochloride inhibits* tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .

HY-117809

PDK1-IN-2	PDK-1	Cancer
PDK1-IN-2 is a small molecule inhibitor of 3-phosphoinositol-dependent protein kinase-1 (PDK1). PDK1-IN-2 inhibits the binding of *PDK1* to its substrate by competitively binding to the PIF pocket of *PDK1, thereby inhibiting* the kinase activity and downstream signaling of *PDK1. PDK1-IN-2* can be used for cell survival and proliferation in cancer .

HY-157299

PDK-IN-3	PDHK	Cancer
PDK-IN-3 (compound 1) is a potent pan inhibitor of PDK with IC₅₀s of 109.3, 135.8, 458.7 nM and 8.67 μM against PDK 1-4, respectively. PDK-IN-3 also induces proliferation and apoptosis in A549 cells .

HY-16461

Solenopsin (-)-Solenopsin A	Akt Ribosomal S6 Kinase (RSK) PI3K PDK-1 FOXO Mitophagy Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Cardiovascular Disease
Solenopsin ((-)-Solenopsin A) is an ATP-competitive and selective Akt-1 inhibitor with an IC₅₀ of 5-10 μM, and also acts as an RSK1 inhibitor. Solenopsin inhibits the activities of *PDK1* in lipid rafts, downregulates PI3K, blocks PI3K-dependent generation of 3-phosphoinositides, and suppresses the phosphorylation of FOXO1a. Solenopsin induces Mitophagy and ROS production, reduces mitochondrial oxygen consumption, and exhibits antiproliferative and antiangiogenic activities. Solenopsin can be used in research related to hyperproliferative skin diseases and malignant diseases .

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer .

HY-149275

PKM2/PDK1-IN-1	Pyruvate Kinase PDK-1 Akt EGFR Apoptosis	Cancer
PKM2/PDK1-IN-1, one of shikonin thioether derivatives, is a dual inhibitor of *PKM2/PDK1*. PKM2/PDK1-IN-1 inhibits the proliferation of NSCLC cells, and induces apoptosis. PKM2/PDK1-IN-1 induces intercellular ROS production, and regulates the apoptotic proteins, to involves in mitochondrial and death receptor pathway .

HY-124060

PS423	PDK-1	Cancer
PS423 is a prodrug of PS210, acting as a substrate-selective inhibitor of *PDK1, inhibiting* the phosphorylation and activation of S6K. PS210 is a potent and selective PDK1 activator targeting the PIF binding pocket of PDK1 .

HY-129426

**PDK1/Akt/Flt dual pathway inhibitor**	Akt	Cancer
PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .

HY-10547R

OSU-03012 (Standard) AR-12 (Standard); PDK1 inhibitor AR-12 (Standard)	Reference Standards PDK-1 Autophagy	Cancer
OSU-03012 (Standard) is the analytical standard of OSU-03012 (HY-10547). This product is intended for research and analytical applications. OSU-03012 (AR-12; PDK1 inhibitor AR-12) is a blood-brain permeable PDK-1 inhibitor with an IC₅₀ of 5 μM .

HY-177913

OSU-02067	PDK-1	Cancer
OSU-02067 is a selective 3-phosphoinositide-dependent protein kinase-1 (PDK-1) inhibitor (IC₅₀=9 μM). OSU-02067 is promising for research of solid tumors (e.g., prostate, breast, colorectal cancers) .

HY-12482

X-370	PI3K Apoptosis PDK-1 MEK Akt ERK	Cancer
X-370 is a PI3Kδ inhibitor (IC₅₀ = 7 nM). X-370 inhibits the survival of leukemia cells, inducing G1 arrest and apoptosis. X-370 blocks *PDK1* binding and phosphorylation of MEK1/2, eliminating Akt and Erk1/2 signaling. X-370 can be used in research on B-cell acute lymphoblastic leukemia (B-ALL) .

HY-172142

PDK1-IN-4	PDK-1	Cancer
PDK1-IN-4 (Compound R-29) is a *PDK1* inhibitor. PDK1-IN-4 can be used for research of lung cancer .

HY-13844

PDK1-IN-3	PDK-1	Cancer
PDK1-IN-3 (Compound C) is a *PDK1* inhibitor, with an IC₅₀ of 34 nM .

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-N0645S

Dicoumarol-d8 Dicumarol-d₈	Isotope-Labeled Compounds PDHK	Cancer
Dicoumarol-d₈ (Dicumarol-d₈) is the deuterium labeled Dicoumarol. Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and PDK1 with IC₅₀s of 0.37 and 19.42 μM, respectively.

HY-N0047R

Polyphyllin I (Standard)	Reference Standards JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I (Standard) is the analytical standard of Polyphyllin I. This product is intended for research and analytical applications. Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of PDK1/Akt/mTOR signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-156109

PDK-IN-2	PDHK Mitochondrial Metabolism	Cancer
PDK-IN-2 (Compound 1F) is a PDK inhibitor (IC₅₀: 68 nM). PDK-IN-2 inhibits the cellular expression of PDK1 and PDK4. PDK-IN-2 enhances mitochondrial bioenergetics, attenuates glycolytic phenotypes, and induces cell apoptosis in the mitochondrial pathway. PDK-IN-2 inhibits tumor growth in 4T1 syngeneic mice model .

HY-156375

PKM2 activator 6	Pyruvate Kinase PDK-1	Cancer
PKM2 activator 6 (Compound Z10) is a PKM2 activator and *PDK1* inhibitor (K_D: 121 and 19.6 μM respectively). PKM2 activator 6 induces colorectal cell apoptosis, and inhibits cell proliferation and migration . PKM2 activator 6 inhibits glycolysis. PKM2 activator 6 inhibits proliferation of DLD-1, HCT-8, HT-29, MCF-10A cells (IC₅₀: 10.04, 2.16, 3.57, 66.39 μM) .

HY-179501

PDK1-IN-5	PDK-1 Reactive Oxygen Species (ROS) Apoptosis Oxidative Phosphorylation	Cancer
PDK1-IN-5 is a selective *PDK1* inhibitor. PDK1-IN-5 activaties PDH by diminishing phosphorylation level via *PDK1* inhibition. PDK1-IN-5 effectively reverses the Warburg effect and shifts cellular energy metabolism from glycolysis toward oxidative phosphorylation by increased acetyl-CoA, reduced lactate, elevated mitochondrial ROS, and subsequent induction of apoptosis. PDK1-IN-5 robustly inhibits tumor growth in vivo without inducing systemic toxicity. PDK1-IN-5 can be used for lung adenocarcinoma, human non-small cell lung adenocarcinoma and gastric colorectal .

HY-175770

mIDH1-IN-2	Isocitrate Dehydrogenase (IDH) PDK-1 Apoptosis	Cancer
mIDH1-IN-2 is a brain-penetrant isocitrate dehydrogenase 1 (IDH1) inhibitor. mIDH1-IN-2 shows subnanomolar potency against IDH1 R132H and R132C (IC₅₀ = 80.0 and 58.0 nM) and minimal activity against wt-IDH1/2. mIDH1-IN-2 also inhibits PDK1 (IC₅₀ = 0.61 μM) and reduces PDH phosphorylation dose-dependently. mIDH1-IN-2 can inhibit cells proliferation, induces S phase arrest and promotes apoptosis. mIDH1-IN-2 can be used for the research of cancer, such as glioma .

HY-119134

PX-316	Akt	Cancer
PX-316 is an Akt inhibitor. PX-316 can phosphorylate Akt, but does not inhibit the phosphorylation of PDK1 or PKC. PX-316 uniquely increases the expression of a group of mitochondrial-related genes. PX-316 can be used for the study of colon cancer and breast cancer .

HY-N17990

Sexangularetin 3-sophoroside	PDK-1 Akt GSK-3 Reactive Oxygen Species (ROS)	Neurological Disease
Sexangularetin 3-sophoroside is a *PDK1* and Akt phosphorylation activator with neuroprotective properties. Sexangularetin 3-sophoroside restores phosphorylated GSK-3β protein levels. Sexangularetin 3-sophoroside acts as a ROS inhibitor and regulates mRNA expression of superoxide dismutase 1 and catalase. Sexangularetin 3-sophoroside can be used for the research of Parkinson’s disease .

HY-10514R

BX795 (Standard)	Reference Standards PDK-1 IKK Autophagy	Cancer
BX795 (Standard) is the analytical standard of BX795 (HY-10514). This product is intended for research and analytical applications. BX795 is a potent and selective inhibitor of PDK1, with an IC₅₀ of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-181670

WH23	Androgen Receptor c-Myc Akt mTOR ERK PDK-1 PI3K Apoptosis	Metabolic Disease Cancer
WH23 is a dehydrogenase/reductase SDR family member 11 (DHRS11) inhibitor with IC₅₀ values of 0.037 μM. WH23 binds to DHRS11, forming a hydrogen bond with the enzyme’s His210 residue. WH23 suppresses androgen receptor mRNA and protein expression, reduces c-Myc expression, and inhibits cancer cell proliferation. WH23 inhibits PI3K/AKT signaling by reducing phosphorylation of *PDK1, AKT, mTOR, and ERK. WH23 enhances Capivasertib (HY-15431)-induced cytotoxicity and apoptosis*. WH23 can be used for the research of luminal androgen receptor-positive triple-negative breast cancer .

HY-183583

HIF-2α-IN-18	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC₅₀ of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and *PDK1*. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma^[1].

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

1,078 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,078 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area